Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL-5), ...

ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in hypereosinophilic syndrome (HES), the phase III NATRON trial showed. Once-monthly ...

Please provide your email address to receive an email when new articles are posted on . Clinical remission meant no exacerbations, no maintenance oral corticosteroid use and well-controlled asthma. A ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients on benralizumab had more significant change ...